Immunogenicity of ALVAC-HIV vCP1521 in Infants of HIV-1-Infected Women in Uganda (HPTN 027): The First Pediatric HIV Vaccine Trial in Africa

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 3, 2014, Pages 268-277

  Kaleebu, Pontiano ^a   Njai, Harr Freeya ^a   Wang, Lei ^b   Jones, Norman ^c   Ssewanyana, Isaac ^d   Richardson, Paul ^e   Kintu, Kenneth ^f   Emel, Lynda ^b   Musoke, Philippa ^e,g   Fowler, Mary Glenn ^f   Ou, San San ^b   Jackson, J Brooks ^f   Guay, Laura ^h   Andrew, Philip ⁱ   Baglyos, Lynn ^j   Cao, Huyen ^c  

^a UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^b Fred Hutchinson Cancer Research Center   (United States)

^c VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^d JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g MAKERERE UNIVERSITY   (Uganda)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

ⁱ FAMILY HEALTH INTERNATIONAL   (United States)

^j SANOFI PASTEUR   (France)

more..

Author keywords

Africa; HIV prevention; HIV vaccine; immunogenicity; infants

Indexed keywords

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; CELL PROLIFERATION; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; PLACEBOS; PREGNANCY; TREATMENT OUTCOME; UGANDA; VACCINATION;

EID: 84894499997     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/01.qai.0000435600.65845.31     Document Type: Article

References (46)

1. Bertolli J, St Louis ME, Simonds RJ, et al. Estimating the timing of mother-To-child transmission of human immunodeficiency virus in a breast-feeding population in Kinshasa, Zaire. J Infect Dis. 1996;174: 722-726
2. Ekpini ER, Wiktor SZ, Satten GA, et al. Late postnatal mother-To-child transmission of HIV-1 in Abidjan, Cote d'Ivoire. Lancet. 1997;349: 1054-1059
3. Miotti PG, Taha TE, Kumwenda NI, et al. HIV transmission through breastfeeding: A study in Malawi. JAMA. 1999;282:744-749
4. Nduati R, John G, Mbori-Ngacha D, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomized clinical trial. JAMA. 2000;283:1167-1174
5. Leroy V, Karon JM, Alioum A, et al. Postnatal transmission of HIV-1 after a maternal short-course zidovudine peripartum regimen in West Africa. AIDS. 2003;17:1493-1501
6. WHO Collaborative Study Team. Role of breastfeeding on the prevention of infant mortality. Effect of breastfeeding on infant and child mortality due to infectious diseases in less developed countries: A pooled analysis. Lancet. 2000;355:451-455
7. Fowler MG, Bertolli J, Nieburg P. When is breastfeeding not best? The dilemma facing HIV-infected women in resource-poor settings. JAMA. 1999;282:781-783
8. Humphrey J, Iliff P. Is breast not best? Feeding babies born to HIVpositive mothers: Bringing balance to a complex issue. Nutr Rev. 2001; 59:119-127
9. Kafulafula G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and gastroenteritis-Associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr. 2010;53:6-13
10. Onyango-Makumbi C, Bagenda D, Mwatha A, et al. Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda. J Acquir Immune Defic Syndr. 2010;53:20-27
11. UNAIDS. Countdown to Zero: Global Plan Towards the Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive. UNAIDS. 2011. Geneva, Switzerland
12. Nachega JB, Uthman OA, Anderson J, et al. Adherence to ART during and after pregnancy in low-income, middle-income, and high-income countries: A systematic review and meta-Analysis. AIDS. 2012;26:2039-2052
13. Myer L, Cornell M, Fox M, et al; IeDEA-Southern Africa Collaboration. Loss to follow-up and mortality among pregnant and non-pregnant women initiating antiretroviral therapy across South Africa: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, DC, 5-8 March 2012. Abstract #22
14. Mofenson LM. Prevention of mother-To-child HIV-1 transmission-why we still need a preventive HIV immunization strategy. J Acquir Immune Defic Syndr. 2011;58:359-362
15. Kintu K, Andrew P, Musoke P, et al. Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: Results from the first vaccine trial in Africa. J Acquir Immune Defic Syndr. 2013;63:1-8
16. Cunningham CK, Wara DW, Kang M, et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clin Infect Dis. 2001;32: 801-807
17. Johnson DC, McFarland EJ, Muresan P, et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis. 2005;192:2129-2133
18. Borkowsky W, Wara D, Fenton T, et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis. 2000;181:890-896
19. McFarland EJ, Johnson DC, Muresan P, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS. 2006; 20:1481-1489
20. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220
21. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366:1275-1286
22. Fang ZY, Kuli-Zade I, Spearman P. Efficient human immunodeficiency virus (HIV)-1 Gag-Env pseudovirion formation elicited from mammalian cells by a canarypox HIV vaccine candidate. J Infect Dis. 1999;180: 1122-1132
23. Moodie Z, Huang Y, Gu L, et al. Statistical positivity criteria for the analysis of ELISPOT assay data in HIV-1 vaccine trials. J Immunol Methods. 2006;315:121-132
24. Peiperl L, Morgan C, Moodie Z, et al. Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: A randomized clinical trial (HVTN 054). PLoS One. 2010; 5:e13579
25. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: A double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011;11:507-515
26. de Souza MS, Ratto-Kim S, Chuenarom W, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol. 2012;188:5166-5176
27. Abate G, Eslick J, Newman FK, et al. Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis. 2005;192:1362-1371
28. Robinson HL. HIV/AIDS vaccines: 2007. Clin Pharm Ther. 2007;82: 686-693
29. McMichael AJ. HIV vaccines. Annu Rev Immunol. 2006;24:227-255
30. Goepfert PA, Horton H, McElrath MJ, et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis. 2005;192:1249-1259
31. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol. 2005;12: 1-12
32. Siegrist CA. Neonatal and early life vaccinology. Vaccine. 2001;19: 3331-3346
33. Adkins B, Leclerc C, Marshall-Clarke S. Neonatal adaptive immunity comes of age. Nat Rev Immunol. 2004;4:553-564
34. Cao H, Kaleebu P, Hom D, et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV Network for Prevention Trials 007 vaccine study. J Infect Dis. 2003;187:887
35. Verrier F, Burda S, Belshe R, et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol. 2000;74:10025-10033
36. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004;78:13232-13252
37. Weber J, Fenyö EM, Beddows S, et al. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J Virol. 1996;70:7827-7832
38. Ssemwanga D, Ndembi N, Lyagoba F, et al. HIV type 1 subtype distribution, multiple infections, sexual networks, and partnership histories in female sex workers in Kampala, Uganda. AIDS Res Hum Retroviruses. 2012;28:357-365
39. Yirrell DL, Kaleebu P, Morgan D, et al. Inter-And intra-genic intersubtype HIV-1 recombination in rural and semi-urban Uganda. AIDS. 2002; 16:279-286
40. Ferrari G, Humphrey W, McElrath MJ, et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci USA 1997;94:1396-1401
41. Buseyne F, Chaix ML, Fleury B, et al. Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. Virology. 1998; 250:316-324
42. Lynch JA, deSouza M, Robb MD, et al. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J Infect Dis. 1998;178: 1040-1046
43. Fukada K, Tomiyama H, Wasi C, et al. Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1-infected Thai and Japanese patients. AIDS. 2002;16:701-711
44. Thomson MM, Pérez-Alvarez L, Nájera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis. 2002;2:461-471
45. Yusim K, Kesmir C, Gaschen B, et al. Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol. 2002;76:8757-8768
46. van der Groen G, Nyambi PN, Beirnaert E, et al. Genetic variation of HIV type 1: Relevance of interclade variation to vaccine development. AIDS Res Hum Retroviruses. 1998;14:S211-S221